Bleakley Financial Group LLC Invests $759,000 in Exelixis, Inc. $EXEL

Bleakley Financial Group LLC acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 17,222 shares of the biotechnology company’s stock, valued at approximately $759,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of EXEL. Fuller & Thaler Asset Management Inc. boosted its position in Exelixis by 2.2% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after acquiring an additional 164,134 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Exelixis by 73.8% in the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after purchasing an additional 2,926,884 shares in the last quarter. Invesco Ltd. boosted its holdings in Exelixis by 40.2% during the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after purchasing an additional 1,596,948 shares during the last quarter. Nuveen LLC bought a new position in Exelixis in the first quarter valued at $123,310,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Exelixis by 2.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company’s stock valued at $122,626,000 after buying an additional 69,054 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Up 1.8%

NASDAQ:EXEL opened at $38.72 on Friday. Exelixis, Inc. has a 12-month low of $27.86 and a 12-month high of $49.62. The firm has a market capitalization of $10.42 billion, a price-to-earnings ratio of 18.62, a P/E/G ratio of 0.78 and a beta of 0.38. The stock’s 50 day moving average price is $38.68 and its two-hundred day moving average price is $40.08.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same period in the previous year, the company posted $0.84 EPS. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Equities research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Wells Fargo & Company reduced their price objective on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 21st. Citigroup reissued a “market outperform” rating on shares of Exelixis in a research report on Tuesday. William Blair restated an “outperform” rating on shares of Exelixis in a research note on Tuesday, July 29th. Stifel Nicolaus upped their price objective on Exelixis from $38.00 to $41.00 and gave the stock a “hold” rating in a research note on Tuesday, July 29th. Finally, Leerink Partnrs raised shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.53.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.